journal article·2019-08

Acetalated Dextran Nanoparticles Loaded into an Injectable Alginate Cryogel for Combined Chemotherapy and Cancer Vaccination

Tomás Bauleth‐Ramos, Ting‐Yu Shih, Mohammad‐Ali Shahbazi, Alexander J. Najibi, Angelo S. Mao, Dongfei Liu, Pedro Granja, Hélder A. Santos, Bruno Sarmento, David J. Mooney

Advanced Functional Materials· Volume 29· Issue 35
Publisher page

Abstract

Abstract Vaccination represents a promising strategy for cancer therapy due to its ability to efficiently eliminate tumors from the host body and prevent their recurrence. Nevertheless, the current vaccines are still lacking efficacy. Combination therapies, such as those integrating chemotherapy with immunotherapy, represent a powerful tool to potentially circumvent this drawback. Herein, injectable alginate cryogels loaded with granulocyte‐macrophage colony‐stimulating factor and cytosine‐phosphodiester‐guanine‐rich oligonucleotides, are combined with spermine‐modified acetalated dextran nanoparticles (Sp‐AcDEX NPs), loaded with p53 activator Nutlin‐3a (Nut‐3a) for combined chemoimmunotherapy. The Sp‐AcDEX NPs are successfully loaded into the alginate cryogels and released over time. Furthermore, the delivery of the NPs from the cryogel enhances their accumulation in tumor tissue following peritumoral injection. Nut‐3a exerts toxicity towards the tumor cells and induces immunogenic cell death through the upregulation of surface calreticulin expression. Overall, this combination is a promising strategy to reduce cancer cell proliferation, induce immunogenic cell death, and accumulate drug payloads into the tumor. This approach may avoid cancer recurrence through the induction of in situ cancer vaccination mediated by antigens and danger signals released from the apoptotic cancer cells.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer Research and Treatments · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Drug Research Program Division of Pharmaceutical Chemistry and Technology Faculty of Pharmacy University of Helsinki FI‐00014 Helsinki Finland

Instituto de Investigação e Inovação em Saúde (I3S) University of Porto Rua Alfredo Allen, 208 4200‐135 Porto Portugal

Instituto de Engenharia Biomédica (INEB) University of Porto Rua Alfredo Allen, 208 4200‐135 Porto Portugal

Instituto Ciências Biomédicas Abel Salazar (ICBAS) University of Porto Rua Jorge Viterbo 228 4150–180 Porto Portugal

John A. PaulsonSchool of Engineering and Applied Sciences Harvard University Cambridge MA 02138 USA

Wyss Institute for Biologically Inspired Engineering Harvard University Cambridge MA 02138 USA

Department of Pharmaceutical Nanotechnology School of Pharmacy Zanjan University of Medical Sciences 56184‐45139 Zanjan Iran

Helsinki Institute of Life Science (HiLIFE) University of Helsinki FI‐00014 Helsinki Finland

CESPU Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde & Instituto Universitário de Ciências da Saúde 4585‐116 Gandra Portugal

Funding

Fundação para a Ciência e a Tecnologia · European Regional Development Fund · Academy of Finland · Sigrid Juséliuksen Säätiö · European Research Council · National Science Foundation

References (43)

Show source-provided references
1. 10.1038/nrclinonc.2014.11110.1038/nrclinonc.2014.111 ↗
2. 10.1016/bs.ai.2015.12.00110.1016/bs.ai.2015.12.001 ↗
3. 10.1007/s12185-011-0799-610.1007/s12185-011-0799-6 ↗
4. 10.1038/nrc.2017.7410.1038/nrc.2017.74 ↗
5. 10.1097/PPO.0b013e318233e5b210.1097/PPO.0b013e318233e5b2 ↗
6. 10.1007/s12274-018-2162-110.1007/s12274-018-2162-1 ↗
7. 10.1038/s41563-018-0147-910.1038/s41563-018-0147-9 ↗
8. 10.1158/2326-6066.CIR-15-011210.1158/2326-6066.CIR-15-0112 ↗
9. 10.1038/nbt.311910.1038/nbt.3119 ↗
10. 10.1038/nature0860110.1038/nature08601 ↗
11. 10.1021/acs.chemrev.5b0010910.1021/acs.chemrev.5b00109 ↗
12. 10.1002/adfm.20170330310.1002/adfm.201703303 ↗
13. 10.1002/adma.20160323910.1002/adma.201603239 ↗
14. 10.1016/j.copbio.2016.02.00110.1016/j.copbio.2016.02.001 ↗
15. 10.1016/j.cell.2015.03.03710.1016/j.cell.2015.03.037 ↗
16. 10.1002/smtd.20170034710.1002/smtd.201700347 ↗
17. 10.1126/scitranslmed.300035910.1126/scitranslmed.3000359 ↗
18. 10.1038/nbt.307110.1038/nbt.3071 ↗
19. 10.1038/ncomms855610.1038/ncomms8556 ↗
20. 10.1002/adhm.20170146910.1002/adhm.201701469 ↗
21. 10.1016/B978-0-12-813339-2.00001-310.1016/B978-0-12-813339-2.00001-3 ↗
22. 10.1016/j.biomaterials.2014.07.05010.1016/j.biomaterials.2014.07.050 ↗
23. 10.1016/j.molonc.2015.10.01610.1016/j.molonc.2015.10.016 ↗
24. 10.1073/pnas.121151610910.1073/pnas.1211516109 ↗
25. 10.1158/0008-5472.CAN-16-283210.1158/0008-5472.CAN-16-2832 ↗
26. 10.1126/science.109247210.1126/science.1092472 ↗
27. 10.2174/13816121179522258610.2174/138161211795222586 ↗
28. 10.1038/nri.2016.9910.1038/nri.2016.99 ↗
29. 10.1016/j.progpolymsci.2011.06.00310.1016/j.progpolymsci.2011.06.003 ↗
30. 10.1039/C1SM06513K10.1039/C1SM06513K ↗
31. 10.1073/pnas.090159210610.1073/pnas.0901592106 ↗
32. 10.1021/ja803947s10.1021/ja803947s ↗
33. 10.3389/fonc.2016.0000710.3389/fonc.2016.00007 ↗
34. 10.1038/natrevmats.2016.7110.1038/natrevmats.2016.71 ↗
35. 10.1371/journal.pone.013510110.1371/journal.pone.0135101 ↗
36. 10.1038/sj.cdd.440226910.1038/sj.cdd.4402269 ↗
37. 10.1038/nm152310.1038/nm1523 ↗
38. 10.1189/jlb.070745910.1189/jlb.0707459 ↗
39. 10.1039/C8NR05933K10.1039/C8NR05933K ↗
40. 10.1038/natrevmats.2016.1410.1038/natrevmats.2016.14 ↗
41. 10.1021/bc100542r10.1021/bc100542r ↗
42. 10.1081/PDT-12001751710.1081/PDT-120017517 ↗
43. 10.1016/j.biomaterials.2013.11.04410.1016/j.biomaterials.2013.11.044 ↗